64532-22-5

Basic information

• Product Name: 6-HYDROXY-2-METHYLPYRIMIDINE-4-ACETIC ACID METHYL ESTER
• Synonyms: 6-HYDROXY-2-METHYLPYRIMIDINE-4-ACETIC ACID METHYL ESTER;methyl (6-hydroxy-2-methylpyrimidin-4-yl)acetate;methyl 6-hydroxy-2-methylpyrimidine-4-carboxylate;Methyl 2-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxylate;Methyl 4-hydroxy-2-methylpyrimidine-6-carboxylate;4-Pyrimidinecarboxylic acid, 1,6-dihydro-2-methyl-6-oxo-, methyl ester
• CAS NO: 64532-22-5
• Molecular Formula: C8H10N2O3
• Molecular Weight: 182.18
• Mol File: 64532-22-5.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 312.359 °C at 760 mmHg
• Flash Point: 142.71 °C
• Appearance: /
• Density: 1.271 g/cm³
• Vapor Pressure: 0.00695mmHg at 25°C
• Refractive Index: 1.568
• CAS DataBase Reference: 6-HYDROXY-2-METHYLPYRIMIDINE-4-ACETIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 6-HYDROXY-2-METHYLPYRIMIDINE-4-ACETIC ACID METHYL ESTER(64532-22-5)
• EPA Substance Registry System: 6-HYDROXY-2-METHYLPYRIMIDINE-4-ACETIC ACID METHYL ESTER(64532-22-5)

Safety Data

• Hazardous Substances Data: 64532-22-5(Hazardous Substances Data)

Usage

General Description

6-HYDROXY-2-METHYLPYRIMIDINE-4-ACETIC ACID METHYL ESTER is a chemical compound with the molecular formula C8H9N3O4. It is a methyl ester derivative of 6-hydroxy-2-methylpyrimidine-4-acetic acid, which is a metabolite of the anti-cancer drug, tegafur. 6-HYDROXY-2-METHYLPYRIMIDINE-4-ACETIC ACID METHYL ESTER is used in the synthesis of pharmaceuticals and as a research chemical in organic chemistry. It has potential applications in the development of new drugs and is also used as a building block in organic synthesis. It is important to handle this chemical with care and use appropriate safety precautions when working with it in the laboratory.

InChI:InChI=1/C7H8N2O3/c1-4-8-5(7(11)12-2)3-6(10)9-4/h3H,1-2H3,(H,8,9,10)

Upstream product

• 67-56-1 methanol 
• 201230-82-2 carbon monoxide 
• 17551-52-9 2-methyl-4-hydroxy-6-chloropyrimidine 
• 1780-26-3 2,4-dichloro-2-methylpyrimidine 

Downstream Products

• 1112178-37-6 N-(3-methoxybenzyl)-2-methyl-6-(2H-tetrazol-5-yl)pyrimidine-4-carboxamide 
• 1112178-44-5 N-(4-fluoro-3-methoxybenzyl)-2-methyl-6-(2H-tetrazol-5-yl)pyrimidine-4-carboxamide 
• 1112169-64-8 N-(4-fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide 
• 1112169-66-0 N-(4-fluoro-3-methoxybenzyl)-6-(2-(((2R,5S)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide 
• 1112170-12-3 (2S,5S)-5-((5-(6-((4-fluoro-3-methoxybenzyl)carbamoyl)-2-methylpyrimidin-4-yl)-2H-tetrazol-2-yl)methyl)-1,4-dioxane-2-carboxylic acid 

Relevant articles and documents

-

-

Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis

Matrix metalloproteinase-13 (MMP-13) is a zinc-dependent protease responsible for the cleavage of type II collagen, the major structural protein of articular cartilage. Degradation of this cartilage matrix leads to the development of osteoarthritis. We previously have described highly potent and selective carboxylic acid containing MMP-13 inhibitors; however, nephrotoxicity in preclinical toxicology species precluded development. The accumulation of compound in the kidneys mediated by human organic anion transporter 3 (hOAT3) was hypothesized as a contributing factor for the finding. Herein we report our efforts to optimize the MMP-13 potency and pharmacokinetic properties of non-carboxylic acid leads resulting in the identification of compound 43a lacking the previously observed preclinical toxicology at comparable exposures.